<DOC>
	<DOC>NCT00568503</DOC>
	<brief_summary>This will be a single dose Proof-of-Concept study in mild-to-moderate COPD patients. The study will investigate the safety and tolerability of QAX028 as well as the bronchodilatory effects of QAX028 compared to tiotropium and placebo in mild-to-moderate COPD patients.</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.</brief_title>
	<detailed_description />
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Male or female patients aged 4075 years with diagnosis of mild or moderate COPD Current or Xsmokers with a smoking history of &gt;10 packyears. Screening ipratropium postbronchodilation FEV1 at 1 h postdose will be greater than 50% of the normal predicted FEV1 value. Patients who can not comply with the following washout periods for standard COPD treatments as follows should be excluded: Shortacting bronchodilators Longacting bronchodilators Inhaled steroids Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>COPD/TIOTROPIUM/QAX028</keyword>
</DOC>